articleThe LancetOct 1, 2006Closed access

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

GDGeorge D. DemetriATAllan T. van OosteromCRChristopher R. GarrettMEMartin E. BlacksteinMHManisha H. Shah

Dana-Farber Cancer Institute · Harvard University · +18 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

2,593
total citations
FWCI
87.71
Percentile
100%
References
41
Citations per year

Authors

17

Topics & keywords

Topics
Keywords
  • Medicine
  • Sunitinib
  • Tolerability
  • Internal medicine
  • Placebo
  • Discontinuation
  • Adverse effect
  • Interim analysis
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.